Skip to content
value.today
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

Total raised
$79 M
3 rounds on record
Latest round
$56 M
Mar 2020
First round on record
Apr 2016
Today
Went public
See the company page

Keros Therapeutics, Inc. is listed today as Keros Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Keros Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$56 MNo. 3$50 to $250 million

Keros Therapeutics, Inc.: Raise no. 3, Mar 2020

Investors in this round

20 investors had bought by the notice of Mar 12, 2020: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Keros Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claudia Ordonez · Executive Officer
  • Jasbir Seehra · Executive Officer, Director
  • Jenn Lachey · Executive Officer
  • Keith Regnante · Executive Officer
  • Alon Lazarus · Director
  • Carl Gordon · Director
  • Julius Knowles · Director
  • Nima Farzan · Director
  • Ran Nussbaum · Director
  • Zafrira Avnur · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jasbir Seehra, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 12, 2020. Read the notice at the SEC.

equitySEC
Nov 2018$12 MNo. 2$10 to $50 million

Keros Therapeutics, Inc.: Raise no. 2, Nov 2018

Investors in this round

9 investors had bought by the notice of Nov 21, 2018: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Keros Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $23 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jasbir S. Seehra · Executive Officer, Director
  • Alon S. Lazarus · Director
  • Julius S. Knowles · Director
  • Ohad S. Hammer · Director
  • Ran S. Nussbaum · Director
  • Zafrira S. Avnur · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jasbir S. Seehra, President. Source: SEC Form D, newest notice filed Nov 21, 2018. Read the notice at the SEC.

equitySEC
Apr 2016$11 MNo. 1$10 to $50 million

Keros Therapeutics, Inc.: Raise no. 1, Apr 2016

Investors in this round

7 investors had bought by the notice of Nov 13, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Keros Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jasbir S. Seehra · Executive Officer, Director
  • Alon S. Lazarus · Director
  • Julius S. Knowles · Director
  • Ohad S. Hammer · Director
  • Ran S. Nussbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jasbir S. Seehra, President. Source: SEC Form D and 2 amendments, newest notice filed Nov 13, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Keros Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License revenue $205.36 million (84%), License revenue $205.36 million (84%), Service and other revenue $38.71 million (16%).

    Annual report (SEC XBRL) · Dec 2025

  • Keros Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2020

Products and services#

No products or services of Keros Therapeutics, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Keros Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arkin Bio Venture Partners Ltd.Venture capitalnot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Arkin Bio Ventures Limited PartnershipVenture capitalnot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Jasbir SeehraPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C preferred stock, director (Form 3, 2020)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series C preferred stock, director (Form 3, 2020)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series C preferred stock, director (Form 3, 2020)SEC Form 3
Pontifax (Cayman) IV L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pontifax (China) IV L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pontifax (Israel) IV, L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pontifax Late Stage Fund L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pontifax Late Stage GP Ltd.Companynot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pontifax Management 4 G.P. (2015) Ltd.Fund or asset managernot statednot statedHeld Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 20 investors.

Largest shareholders today

Institutions holding Keros Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Keros Therapeutics, Inc.
NameRoleNamed in
Claudia OrdonezExecutive officerMar 2020
Jasbir SeehraExecutive officerMar 2020
Jenn LacheyExecutive officerMar 2020
Keith RegnanteExecutive officerMar 2020
Jasbir S. SeehraExecutive officerNov 2018
Alon LazarusDirectorMar 2020
Carl GordonDirectorMar 2020
Jasbir SeehraDirectorMar 2020
Julius KnowlesDirectorMar 2020
Nima FarzanDirectorMar 2020
Ran NussbaumDirectorMar 2020
Zafrira AvnurDirectorMar 2020
Alon S. LazarusDirectorNov 2018
Jasbir S. SeehraDirectorNov 2018
Julius S. KnowlesDirectorNov 2018
Ohad S. HammerDirectorNov 2018
Ran S. NussbaumDirectorNov 2018
Zafrira S. AvnurDirectorNov 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.